anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an external preparation for acne which contains a plum extract and exerts excellent preventive and therapeutic effects against acne.  &lt;P&gt;SOLUTION: The external preparation for acne contains at least one selected from an antibacterial or germicidal component, a component for softening or peeling the corneum, an anti-inflammatory component and a component for suppressing or absorbing sebum as an active ingredient. Here, the plum extract is added at an amount sufficient for enhancing the effect of the active ingredient, i.e. ≥0.1 wt.% against the weight of the external preparation. The plum extract is obtained from a plum fruit, particularly from a seed (pit) in the fruit.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
By recognizing that impaired endothelium-dependent arterial vasomotor response, or &#34;endothelial dysfunction&#34;, is the central manifestation of both established and pre-clinical atherosclerosis, a nutritional composition has been invented. The composition provides a novel mixture of ingredients each one of which having been chosen on the basis of its demonstrated ability to reverse endothelial dysfunction in individuals suffering from a disease of atherosclerosis or in individuals who are disease-free but carry at least one risk factor for atherosclerosis. The composition consists of pharmacological doses of folic acid, niacin, vitamin C, vitamin E, coenzyme Q, omega-3 polyunsaturated fatty acids, and magnesium salt. It is recognized that any individual who, unpredictably, may be refractory to one or more of the aforementioned agents will likely be responsive to the other agents and thereby receive benefit from the composition as a whole. Furthermore, individuals who are responsive to more than one agent, or all the agents, will enjoy particular benefit from the composition by virtue of the additive effects of the individual agents. Thus, by reversing endothelial dysfunction in at-risk, disease-free individuals, the earliest step of atherogenesis can be blocked and disease development can be prevented; and, by treating individuals afflicted with any one of the diseases of atherosclerosis - coronary artery disease, cerebrovascular disease or peripheral vascular disease - the chance of ischemic attacks can be reduced.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method and a composition for administering capsaicin and other TRPV1 agonists.  &lt;P&gt;SOLUTION: A composition containing a TRPV1 agonist such as capsaicin, and a solvent system are provided. The topical application of the composition rapidly delivers an agonist to the skin and epidermis. A method of using the composition for reducing a nociceptive nerve fiber function in subjects and for treating capsaicin-responsive conditions is also provided. The invention is directed to a method of delivering the TRPV1 agonist to an epidermides and dermis below a mammal&#39;s skin or mucous membrane surface with an area of 1 cm&lt;SP&gt;2&lt;/SP&gt;. The method includes a step of bringing the area into contact with the composition containing the TRPV1 agonist and at least one penetration enhancer; at least about 3 nanomoles of the TRPV1 agonist is held in the epidermides and dermis 30 minutes after the step of bringing the area into contact.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Diseases, aging, trauma, environmental exposure, infection and other events or agents can alter tissue function. In one embodiment, treatment is provided by therapeutically altering tissue function. This may be by continuing normal tissue function, suppressing tissue function, or enhancing tissue function. In a preferred embodiment, this treatment is effectuated by penetrating an organ, organ component or tissue structure and placing a supplemental material in a newly created space. This space is generally referred to herein as a &#39;privileged space&#39;, i.e. a space not otherwise present in native tissue. Supplemental materials can be deposited and secured within the zone. Supplemental materials include materials forming barriers, supports, and/or materials that deliver agents having a pharmacologic, biochemical, or physiologic effect in vivo. Suitable supplemental materials include polymeric and non-polymeric materials, pharmacologic agents, cells, tissue fragments, microorganisms, viral agents, or other reagents modifying tissue function. The supplemental material is typically in the form of a reservoir/depot, or continuous or discontinuous layer. In one embodiment, supplemental materials, and methods of use thereof, are provided for the continuous or discontinuous therapy of defined regions of an organ, organ component or tissue structure. The supplemental materials may be delivered directly to any one or more of the three zones, endoluminal (or ectomural, for solid organs), endomural, or ectoluminal, of organs, organ components, or tissue structures. The supplemental materials can include natural or synthetic polymeric materials that are biodegradable or non-biodegradable. The supplemental materials can also contain bioactive agents to effectuate a change in an organ or organ component in need thereof. For example, agents that result in a reduced/hyponormal response or an amplified/hypernormal response may be included in the supplemental materials.
An integrated continuing medical education and treatment system is implemented as a system, a process, and an article of manufacture. A treatment goal memory stores clinical treatment goal data associated with at least one or more disease. An educational memory stores instructional education data associated with at least one disease and a treatment delta; the treatment delta is the difference between a clinical treatment goal data and corresponding data relevant to a disease of inquiry. A processor is adapted to receive a healthcare provider&#39;s selection of a disease of inquiry and electronic medical record data relevant to any disease of inquiry. The clinical treatment goal data may be queried for a disease matching a disease of inquiry. The goal data is compared with the electronic medical record data to determine a treatment delta. The continuing medical education data is selected based on the disease of inquiry and the treatment delta.
Process for obtaining benzoxazines useful for the synthesis of ofloxacin, levofloxacin and derivatives thereof. The benzoxazines (I) wherein Xb is halogen and R1 is H, alkyl or alkylene up to 6 C atoms or aryl, may be obtained by cyclazation of a compound having the formula (II) by reaction with triphenylphosphin and azodicarboxylate of ethyl. The compounds of formula (II) may be obtained by reaction of a compound (III) with an appropriate epoxy. By using the appropriate chiral epoxy, the enantiomerically desired intermediate may be obtained, and consequently it is possible to selectively obtain the desired final product with the appropriate enantiomer form without having to go through a resolution step. The compounds (I) are valuable and key intermediates for the synthesis of antimicrobial agents such as floxacin and levofloxacin. &lt;CHEM&gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technology for forming an insulin-like growth factor-1 (IGF-1) in the body of an organism such as inside of the blood vessel, organs or skin of the organism by a simple means.  &lt;P&gt;SOLUTION: A gas-liquid two-phase fluid consisting of a liquid mixture of gas and liquid is rotated at a speed of 20,000-40,000 rpm (330-670 rps) in a vessel with a cylindrical or conical inner shape to form the two-phase swirling stream of liquid and gas at the central part of the vessel. A negative pressure hollow part of gas is formed along a rotary axis of the two-phase swirling stream to form a swirling gas hollow part. Gas is cut and crushed by the swirling stream. Functional microbubbles containing fine bubbles with diameters of 10-40 μm and a potential of -40 to -100 mV at the time of generation or functional microbubble water is supplied to organisms (e.g., organisms are dipped in microbubble water).  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain the subject composition containing oil and fat in which n-3-based long-chain polybasic unsaturated fatty acid is distributed in a large amount at 1 position and/or 3 position of glyceride, capable of decreasing blood lipid concentration and having high suppressing effect on blood platelet coagulation ability by using a small amount of the composition. SOLUTION: This oil and fat-containing composition is obtained by blending with preferably 20-100wt.% oil and fat containing, as a fatty acid constituting glyceride, a n-3-based long chain polybasic unsaturated fatty acid (n 3-based fatty acid) in which &lt;40mol% of total amount of the n-3 based fatty acid is a mixed triglyceride which is bound to 2 position of glyceride. Eicosapentaenoic acid and/or docosahexaenoic acid is preferably used as the n-3 based fatty acid. The mixed triglyceride is obtained by mixing, e.g. triglyceride of a fatty acid containing n-3 based fatty acid such as oil and fat of whale in a large amount with a fatty acid not containing n-3 based fatty acid or containing a small amount of n-3 based fatty acid to carry out transesterification.  A lipase having specificity at 1,3-position of glyceride, e.g. porcine pancreas lipase is preferably used as the transesterification catalyst.
A method for preparing the medicine &#39;Ruhepi powder&#39; for treating mastopathy includes such steps as dissolving the medicine in water, adding the medicine, stirring, and stirring. The pain of the patient is increased, the medical expense of the patient is increased, the time for the patient to go to the hospital for treatment is wasted, and the outpatient service volume of the hospital and the workload of medical care personnel are increased. The method is characterized in that: selecting 30g of safflower, 30g of salvia miltiorrhiza, 30g of green tangerine peel, 30g of szechwan chinaberry fruit, 30g of beautiful sweetgum fruit, 30g of tangerine seed, 30g of white paeony root, 60g of common selfheal fruit-spike, 30g of platycodon root, 30g of figwort root, 30g of pangolin scales, 30g of fritillaria, 30g of lychee seed and 30g of red paeony root. Grinding into powder, sieving with a fine sieve of 80-120 meshes, and mixing. The advantages are that: has obvious treatment effect, good effect and short treatment period, and strives for the optimal treatment time for patients. The pain of the patient is reduced, the medical cost of the patient is reduced, and the outpatient service volume of the hospital and the workload of medical care personnel are reduced. For the treatment of breast diseases.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a fine zinc oxide more easily at a low cost, which is suitable for mass production.  &lt;P&gt;SOLUTION: By allowing a silicon compound to be present when a zinc compound is precipitated by an alkali in water of 50°C or above, a fine zinc oxide having a BET specific surface area of 30-100 m&lt;SP&gt;2&lt;/SP&gt;/g is obtained. The product is a composite powder of a coprecipitate containing zinc oxide and silica, and has sufficient ultraviolet ray-shielding capacity, transparency or the like since it contains zinc oxide. The content of zinc in the coprecipitate is preferably 70.0-99.9 wt.% in terms of ZnO. This method does not need special equipment such as a mill and a mixer in the case of reaction which becomes a high viscosity, and therefore mass production is possible.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
A novel wound electrode assembly for a lithium oxyhalide electrochemical cell is described. The electrode assembly comprises an elongate cathode of an electrochemically non-active but electrically conductive carbonaceous material disposed between an inner elongate portion and an outer elongate portion of a unitary lithium anode. That way, lithium faces the entire length of the opposed major sides of the cathode. This inner anode portion/cathode/outer anode portion configuration is rolled into a wound-shaped electrode assembly that is housed inside a cylindrically-shaped casing. A cylindrically-shaped sheet-type spring centered in the electrode assembly presses outwardly to limit axial movement of the electrode assembly. In one embodiment, all the non-active components, except for the cathode current collector which is nickel, are made of stainless-steel. This provides the cell with a low magnetic signature without adversely affecting the cell&#39;s high-rate capability.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a protein stably obtainable and having higher activity of selecting tumor cells than ever.  &lt;P&gt;SOLUTION: The antitumor protein derived from calluses of an Araliaceae plant, a method for producing the protein, and an antitumor agent containing the protein as an active ingredient are provided, respectively. The antitumor protein has higher selectivity on the tumor cells when compared with another protein derived from a plant body of the plant. Because the protein is derived from the calluses, the protein is stably obtainable all the year around, although the plant body is unstable as a source of supplying the protein due to its seasonability. Further, productivity of the protein is expected to be improved by studying conditions of culturing the calluses.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The invention provides a gRNA targeting VEGFR2 and application thereof, wherein a gRNA targeting sequence is selected from a 5&#39; end region of No. 3 exon, no. 15 exon or No. 17 exon of VEGFR 2. The invention also provides an expression vector for expressing the gRNA, a CRISPR-Cas system for targeting VEGFR2 and application of the expression vector and the CRISPR-Cas system. Compared with the prior art, the gRNA has higher editing efficiency on VEGFR2, can effectively inhibit the expression of VEGFR2, and has better treatment effect on diseases caused by the over-expression of VEGFR2, such as cancer, diabetic nephropathy, rheumatoid arthritis, psoriasis skin, ovarian hyperstimulation syndrome, proliferative diabetic retinopathy, mature retinopathy and age-related wet macular degeneration; and the invention utilizes non-viral vectors, and has higher safety.
PROBLEM TO BE SOLVED: To obtain a preparation capable of reducing its administration frequency per day, in particular, in a long-term treatment in order to improving safety and patient&#39;s compliance. SOLUTION: This preparation, an orally administrable solid preparation, contains 0.5-10 pts.wt. of a polyvinylpyrrolidone with an average molecular weight of about 15,000-100,000 or 1 pt.wt. of an amorphous active compound as the coprecipitate in another coprecipitate-forming polymer, and as appropriate, essentially 0.01-15.0 pts.wt. of delayed-release component consisting of a gel-forming polymer, and as appropriate, other auxiliary and additive. This preparation has highly sustainably controlled releasability and high storage stability.
Current kidney organoids model development and diseases of the nephron but not the con-tiguous epithelial network of the kidney&#39;s collecting duct (CD) system. Here, we report the generation of an expandable, 3D branching ureteric bud (UB) organoid culture model that can be derived from primary UB progenitors from mouse and human fetal kidneys, or gen-erated de novo from human pluripotent stem cells. In chemically-defined culture conditions, UB organoids generate CD organoids, with differentiated principal and intercalated cells adopting spatial assemblies reflective of adult kidney&#39;s collecting system. Aggregating 3D-cultured nephron progenitor cells with UB organoids results in a reiterative process of branching morphogenesis and nephron induction, similar to kidney development. Applying a gene editing strategy to remove RET activity, we demonstrate genetically modified UB organoids can model congenital anomalies of kidney and urinary tract (CAKUT). These platforms facilitate an understanding of development, regeneration and diseases of the mammalian collecting system.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a polyphenol having little side effects and excellent action of fibroblast activation and to provide an excellent food supplement and an excellent cosmetic each containing a polyphenol and having little side effects.  &lt;P&gt;SOLUTION: The polyphenol having action of fibroblast activation contains an epigallocatechin derivative. The derivative is composed of a parent nucleus of a polyphenol and any one of teaflavin, ellagic acid, betaine, ascorbic acid, dehydrokraepellic acid, 6-oxooctadecanoic acid, γ-linolenic acid, linoleic acid, oleic acid, palmitic acid, and stearic acid and bonded through an ester linkage to position 3 of ring A of the parent nucleus. A polyphenol is also provided which is obtained by adding cellulase to a pulverized plant material and extracting the product with liquefied carbon dioxide or hexane. The food supplement and the cosmetic each contains the polyphenol having action of fibroblast activation.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method and a composition for remitting the symptom and condition relating to psychosis.  &lt;P&gt;SOLUTION: This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for ameliorting pathologies or conditions associated with psychosis. These pathologies or conditions include psychotic major depression, schizoaffective disorders, Alzheimer&#39;s Disease and cocaine addiction. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for the amelioration of psychosis in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Novel phosphonate compounds are described. The compounds have activity as neuraminidase inhibitors against wild-type and H274Y mutant of H1N1 and H5N1 viruses. The present disclosure also provides an enantioselective synthetic route to known neuraminidase inhibitors oseltamivir and the anti-flu drug Tamiflu®, as well as novel phosphonate compounds, via D-xylose. Another efficient and flexible synthesis of Tamiflu and the highly potent neuraminidase inhibitor Tamiphosphor was also achieved in 11 steps and &gt; 20% overall yields from the readily available fermentation product (1S-cis)-3-bromo-3,5-cyclohexadiene-1,2-diol. Most of the reaction intermediates were obtained as crystals without tedious purification procedures. The key transformations include an initial regio-- and stereoselective bromoamidation of a bromoarene cis- dihydrodiol, as well as the final palladium-catalyzed carbonylation and phosphonylation.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technique for gradually controlling a exothermic way in an exothermic foam cosmetic using heat of reaction of a metal oxide with water as a heat source.  &lt;P&gt;SOLUTION: The exothermic foam cosmetic uses the heat of reaction of the metal oxide with water as the heat source. The exothermic foam cosmetic comprises (1) a composition characterized by comprising the metal oxide coated with a water-soluble polymer and (2) a composition characterized by comprising an acidic substance. The exothermic foamlike cosmetic comprising a foaming agent in a composition containing the (1), (2) or other optional constituent elements is provided. The cosmetic is obtained by filling the two compositions (1) and (2) in a pressure-resistant container. Furthermore, the pressure-resistant container has preferably a structure in which each independent chamber for filling the compositions (1) and (2) and an outlet of the chamber is united in a discharge port.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely urology. 7 days prior to operation and after it complex medical therapy is conducted. Lithotripsy is performed with ultrasonic probe 1.5 mm at an ultrasound power of 80–100 % with a working cycle of 100 % on a fixed stone in a Hachin&#39;s 4x16 &#34;blown&#34; basket, with diameter of 20 mm, 5 Fr. Ureteric stent Ch No. 4.8 is inserted. If it is impossible to fix the stone in the basket due to its size of 2–3 cm, lithotripsy is performed in the centre of the stone with subsequent capture of the fragments into the basket and lithotripsy according to the method described above.EFFECT: method enables reducing a risk of kidney parenchyma damage, hematuria, ureteral trophism disorder, postoperative dysuria, kidney ischemia; avoiding a repeated lithotripsy session, achieving fine fragmentation of the stone, reducing the stent length to 3–5 days and eliminating the risk of stone formation on it.1 cl, 3 ex
PURPOSE:To obtain a lipid metabolism improver having immediate effects free from side effects, containing a calcium hexose phosphate as an active ingredient. CONSTITUTION:A calcium hexose phosphate (e.g. calcium glucose-1-phosphate) and, if necessary, a given carrier for preparation, excipient, etc., are pharmaceuti cally manufactured by a conventional procedure to give the aimed substance. The substance can be made into tablets, granules, capsule agents, oral adminis tration agent, etc. A dose is 0.1-20g, preferably 1-10g calculated as calcium hexose per person daily. Acute toxicity of mouse of calcium glucose-1-phosphate is &gt;=15,000mg/kg and the substance is extremely safe. Since the substance extremely lowers concentration of serum cholesterol, the substance is effective as a preventive and remedy for myocardial infarction, ischemic heart disease and hypercholesterolemia.
PROBLEM TO BE SOLVED: To obtain a new nucleic acid for e.g. production of an animal model of a nerve-denatured disease, comprising a recombinant nucleic acid encoding a protein or peptide involved in a nerve-denatured disease and capable of regenerating a bad regulation of a cell involved in coagulation of protein. SOLUTION: This new recombinant nucleic acid encoding a protein or peptide involved in a nerve-denatured disease is to have been altered as to enable the protein or peptide to concentrate in a predetermined cellar fraction and useful for e.g. producing the cells and animal models of nerve-denatured diseases capable of regenerating a bad regulation of cells involved in concentration of protein. The recombinant nucleic acid is obtained by adding a nucleic acid sequence corresponding to a secretion sequence, which permits a secretion in an endoplasmic reticulum and encodes a series of hydrophobic amino acids, to the upstream of a sequence encoding a β-peptide so as to concentrate a β-amyloid peptide involved in a nerve-denatured disease e.g. Alzheimer&#39;s disease in a predetermined cellar fraction, and by adding a KDEL amino acid linkage to the downstream.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an acne-preventing agent or an anti-obesity agent having a lipase-inhibiting activity.  &lt;P&gt;SOLUTION: A composition contains a kudzu flower and a tea flower that synergistically exhibit a lipase-inhibiting effect. A kudzu flower extract is obtained by adding a solvent to a kudzu flower, a homogenate thereof or a powder thereof and extracting the same. A tea flower extract is obtained by adding a solvent to a tea flower, a homogenate thereof or a dry powder thereof and extracting the same. The composition or a lipase-inhibiting agent can be used as food and beverage or a cosmetic, either directly or after adding various ingredients to the same.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT